Relay Therapeutics

Integrating leading-edge computational and experimental science to transform human health. $RLAY

[Relay Therapeutics @Relay_Tx]

Did you know, many vascular anomalies, including PIK3CA-Related Overgrowth Spectrum (PROS) and #lymphaticmalformations, are caused by mutations or changes in a single gene called PIK3CA? Genetics research continues to advance, and every new discovery helps us better understand these conditions. That's why our team was excited to attend the Annual Genetics Education Symposium: #VascularAnomalies at the @ClevelandClinic to learn from leading experts about the latest advancements in genetics and vascular anomalies. Thank you to the Cleveland Clinic team and all who contributed to a thoughtful, informative day. We’re grateful to keep learning alongside this community.

[Relay Therapeutics @Relay_Tx]

We are pleased to welcome Shannon Campbell to Relay Tx, where she will lead commercial preparations for zovegalisib in breast cancer and vascular anomalies.

Shannon has more than 30 years of experience in pharma and biotech, and has built commercial teams to launch multiple drugs. Most recently, she served as Chief Commercial Officer at Merus and prior to that, led the U.S. Solid Tumor Franchise at Novartis.

We’re thrilled to have her leadership and expertise on the team. Welcome, Shannon!

[Relay Therapeutics @Relay_Tx]

Today, we report third quarter 2026 financial results and corporate updates. We saw meaningful progress in Q3: continued Phase 3 ReDiscover-2 enrollment, now estimated to complete in mid-2027, updated ReInspire vascular anomalies data coming at #ASH26, the appointment of Shannon Campbell to lead commercial preparations for zovegalisib, and a new mutant-selective TIE2 program. Read more: https://t.co/cX0BcQkBab

[Relay Therapeutics @Relay_Tx]

Breast cancer doesn't follow a calendar, and neither does our gratitude.

This #BreastCancerAwarenessMonth, and in every month that follows, we thank the metastatic breast cancer (MBC) community and our partners around the world.

Your knowledge, perspective, and lived experience help us understand what matters to people living with MBC, and keep our work grounded in it. Thank you.

[Relay Therapeutics @Relay_Tx]

Last weekend, the Relay Tx vascular anomalies team was in Virginia for #PeDRA2026! We were proud to present a poster on preliminary results of zovegalisib, a mutant-selective PI3Kα inhibitor, in adult and adolescent patients with PIK3CA-driven vascular malformations. Conversations throughout the conference continued to emphasize the urgency of advancing targeted options for this patient population, and we’re grateful to the PeDRA community for the opportunity to share our work and connect with others working to move this field forward.

[Relay Therapeutics @Relay_Tx]

Congratulations to the Vascular Malformations Centre at Cliniques universitaires Saint-Luc on 35 years of caring for people living with #VascularAnomalies!

We were honored to join #VASCAPADay in Belgium this past weekend for a day of education, exchange, and celebration. It was a privilege to connect with the healthcare professionals, patients and families.

Thank you to @VASCAPA and the Centre team for bringing everyone together. Here's to many more advancements for the vascular anomalies community.

[Relay Therapeutics @Relay_Tx]

We were thrilled to return to Arkansas this year for a family event hosted by the Association of Pediatric Hematology/Oncology Nurses (APHON). Our team enjoyed spending the day with individuals and families living with #VascularAnomalies and hearing their experiences firsthand. Time with this community continues to deepen our understanding of the effects PIK3CA-driven VAs can have on daily life and reaffirms our commitment to the patients and families. Thank you to APHON for another impactful family day!

[Relay Therapeutics @Relay_Tx]

Today is a special day for Relay Therapeutics. The FDA has approved lirafugratinib (brand name LYRFIGTU™) for patients with FGFR2-driven #cholangiocarcinoma, brought to patients by our commercial partner Elevar Therapeutics following our global out-licensing agreement in 2024.

This is the first medicine to emerge from our Dynamo® platform, our approach to studying protein motion with the goal of solving some of the toughest challenges in drug discovery. Relay was founded to make medicines for patients in need, and reaching an approval just 10 years later makes this a landmark validation for our R&D team's approach.

Kudos and Yahzu to the dedicated Relayers who worked relentlessly to discover and develop this drug, congratulations to our partners at Elevar, and a sincere thank you to the patients, families, and investigators who have made this accomplishment possible.

[Elevar Therapeutics @ElevarTx]

Breaking news! The FDA has approved our treatment for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring a FGFR2 fusion or other rearrangement.

Read our #ElevarPressRelease: https://t.co/QcydA8eQso

#ElevarTx #ElevarTherapeutics #ElevatingOutcomes #news

[Relay Therapeutics @Relay_Tx]

There’s nothing quite like that moment when the team crowds around a desk to see promising experimental results.

At Relay Tx, we're grateful for a research team that is committed to tackling some of the toughest targets in drug discovery. This is what it means to work on something that matters.

[Relay Therapeutics @Relay_Tx]

Today, we reported our second quarter financial results and corporate updates. Read more in our Q2 earnings release here. https://t.co/C4nCACVBLx

[Relay Therapeutics @Relay_Tx]

Today, we honor #CLOVES Awareness Day. Community changes what's possible in rare disease. It connects patients and families, informs research, and sustains the push for better care. We're proud to be working alongside @CLOVESSyndrome in this effort. Learn more about CLOVES at https://t.co/cHxdccOS6C.

[Relay Therapeutics @Relay_Tx]

Last weekend, we presented and connected with patients, families, and clinicians at the @KTSupportGroup's 40th Anniversary Conference at the Mayo Clinic. Our conversations at the conference reinforced the acute needs this patient community faces, reminding us of the impact we aim to have as we advance our vascular anomalies program.

Thank you to the KT Support Group for 40 years of advocacy and for the community you've built. Insights from this weekend will continue to shape our work going forward.

[Relay Therapeutics @Relay_Tx]

This past weekend, members of the Relay Tx team volunteered at Betsy's Camp, an overnight camp for children with CLOVES syndrome and their families. Campers and families enjoyed a weekend of archery, ropes courses, arts and crafts, campfires, and meaningful time spent with others who share and understand their experiences.

Moments like these are powerful reminders of our mission and the importance of fostering community, connection, and support for individuals and families navigating vascular anomalies. Thank you to the #CLOVESsyndrome community and Zebra Crossing for making it such a memorable weekend.

[Relay Therapeutics @Relay_Tx]

Relay Tx turned 10 years old and we took to the arcade, like a true 10 year old!

A lot has changed in the past decade:
✔️Jean styles went from skinny to baggy
✔️Our Kendall Square neighborhood continued to grow as a leading biotech hub
✔️Ideas born in our labs are now being investigated in patients around the world

[Relay Therapeutics @Relay_Tx]

May is Lymphatic Malformation Awareness Month, a month dedicated to raising awareness and understanding of the two types of lymphatic malformations: isolated lymphatic malformations and complex lymphatic anomalies. At Relay Tx, we recognize the impact lymphatic malformations can have on individuals and families and remain committed to advancing research for the lymphatic malformations and broader vascular anomalies community.

Learn more about lymphatic malformations and support available to the lymphatic malformation community from the patient advocacy group, @LGDAlliance: https://t.co/6X9UnJoGEA

[Lymphatic Malformation Alliance @LM_Alliance]

Understanding starts here. 💜

For many families, LM and CLA bring more questions than answers. This month, we’re helping change that—through awareness, support, and community.

Learn more: https://t.co/Wn6AwY8taK

#LMAwarenessMonth #MakeRareVisible #RareButNotAlone

[Relay Therapeutics @Relay_Tx]

Today, we announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies, a group of rare disorders characterized by abnormal development of blood vessels, lymphatic vessels, and surrounding tissues. The data, being presented this week at #ISSVA2026, demonstrated symptomatic improvement at 12 weeks in nearly all patients while maintaining a safety and tolerability profile showing potential for chronic use. These findings also support the potential advantage of PI3Kα mutant-selective inhibition. Click below for additional insights and more from President of R&D Don Bergstrom. https://t.co/OhAcGFoNJV

[Relay Therapeutics @Relay_Tx]

Today, we reported first quarter 2026 financial results and highlighted continued progress across our pipeline. Details here. https://t.co/4Hi3Mfprxp

[Relay Therapeutics @Relay_Tx]

Today, we're pleased to announce new clinical data and plans to move zovegalisib + atirmociclib triplet combination into Phase 3 development in frontline patients with PI3Kα-mutated, HR+/HER2- metastatic #breastcancer. We aim to initiate this study early next year. Join us this morning, April 27, at 8:30am ET for our conference call to learn more. https://t.co/eT7plAyP1b

[Relay Therapeutics @Relay_Tx]

In continued recognition of International Children’s Book Day, Relay Tx acknowledges that children’s books can help communicate feelings and experiences related to rare diseases that are often hard to explain.

For families living with vascular anomalies, everyday life can include navigating uncertainty, feelings of isolation, and comments about visible differences that can feel overwhelming, especially for children. By honestly explaining these unique journeys and experiences, children's books can help empower individuals and build understanding and acceptance.

Today, we celebrate stories that shine a light on rare conditions and remind families that their experiences matter. They are not alone.

Learn more about vascular anomalies children’s books and CLOVES Syndrome at https://t.co/z6d1TsPqqw and FAVA at https://t.co/llSfBKRIWx.

[Relay Therapeutics @Relay_Tx]

In the spirit of International Children’s Book Day last week, Relay Tx recognizes the power of children’s books to explain challenging topics in ways that are honest and compassionate.

For families impacted by breast cancer, children's books can help open dialogue, normalize emotions, and remind families that they are not alone. These books can be a gentle way to support understanding, resilience, and connection during challenging moments.

So today, we honor the authors, illustrators, patients, and families who use storytelling as a tool for comfort, courage, and care.

Learn more about children’s books available for the breast cancer community: https://t.co/06u7CtpSEM